Cost-effectiveness of continuous erythropoietin receptor activator in anemia

References

• CulletonBFMannsBJZhangJTonelliMKlarenbachSHemmelgarnBRImpact of anemia on hospitalization and mortality in older adultsBlood2006107103841384616403909
   PubMed Web of Science ®Google Scholar
• WeissGGoodnoughLTAnemia of chronic diseaseN Engl J Med2005352101011102315758012
   PubMed Web of Science ®Google Scholar
• GoodnoughLTSchrierSLEvaluation and management of anemia in the elderlyAm J Hematol2014891889624122955
   PubMed Web of Science ®Google Scholar
• MurphyMFWallingtonTBKelseyPBritish Committee for Standards in Haematology, Blood Transfusion Task ForceGuidelines for the clinical use of red cell transfusionsBr J Haematol20011131243111328275
   PubMed Web of Science ®Google Scholar
• EschbachJWAbdulhadiMHBrowneJKRecombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trialAnn Intern Med19891111299210002688507
   PubMed Web of Science ®Google Scholar
• KDIGO clinical practice guidelines for anemia in chronic kidney diseaseKidney Int Suppl201224288291
   PubMed Web of Science ®Google Scholar
• RizzoJDBrouwersMHurleyPAmerican Society of Hematology and the American Society of Clinical Oncology Practice Guideline Update CommitteeAmerican Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancerBlood2010116204045405920974674
   PubMed Web of Science ®Google Scholar
• rote-liste.de [homepage on the Internet]Frankfurt, GermanyRote Liste® Service GmbH [updated 2014; cited January 23, 2014]. Available from: http://rote-liste.de/Accessed June 13, 2014
   Google Scholar
• CollinsAJFoleyRNHerzogCExcerpts from the US Renal Data System 2009 Annual Data ReportAm J Kidney Dis2010551 Suppl 1S1S420A6
   PubMed Web of Science ®Google Scholar
• BesarabABoltonWKBrowneJKThe effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetinN Engl J Med199833995845909718377
   PubMed Web of Science ®Google Scholar
• SinghAKSzczechLTangKLCHOIR InvestigatorsCorrection of anemia with epoetin alfa in chronic kidney diseaseN Engl J Med2006355202085209817108343
   PubMed Web of Science ®Google Scholar
• DrüekeTBLocatelliFClyneNCREATE InvestigatorsNormalization of hemoglobin level in patients with chronic kidney disease and anemiaN Engl J Med2006355202071208417108342
   PubMed Web of Science ®Google Scholar
• PfefferMABurdmannEAChenCYTREAT InvestigatorsA trial of darbepoetin alfa in type 2 diabetes and chronic kidney diseaseN Engl J Med2009361212019203219880844
   PubMed Web of Science ®Google Scholar
• CurranMPMcCormackPLMethoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney diseaseDrugs20086881139115618484803
   PubMed Web of Science ®Google Scholar
• PanchapakesanUSumualSPollockCNanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin Receptor Activator)Int J Nanomedicine200721333817722510
   PubMed Web of Science ®Google Scholar
• LevinNWFishbaneSCañedoFVMAXIMA study investigatorsIntravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA)Lancet200737095961415142117950856
   PubMed Web of Science ®Google Scholar
• MacdougallICWalkerRProvenzanoRARCTOS Study InvestigatorsCERA corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trialClin J Am Soc Nephrol20083233734718287255
   PubMed Web of Science ®Google Scholar
• LocatelliFMannJFAldigierJCCERA safety profile: a pooled analysis in patients with chronic kidney diseaseClin Nephrol20107329410320129016
   PubMed Web of Science ®Google Scholar
• DellannaFWinklerREBozkurtFMIRACEL Study GroupDosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly CERA: experience from the MIRACEL studyInt J Clin Pract2011651647221091595
   PubMed Web of Science ®Google Scholar
• GasconPPirkerRDel MastroLDurrwellLEffects of CERA (continuous erythropoietin receptor activator) in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemotherapy: results of a phase II studyAnn Oncol201021102029203920335369
   PubMed Web of Science ®Google Scholar
• SchmidtRJMethoxy polyethylene glycol-epoetin beta: worth waiting for or a novelty worn off?Expert Opin Pharmacother20091091509151419505218
   PubMed Web of Science ®Google Scholar
• Patent docs Biotech & Pharma Patent Law & News Blog [webpage on the Internet] Available from: http://www.patentdocs.org/2009/12/amgen-and-hoffmanlaroche-settle-mircera-litigation.htmlAccessed June 8, 2014
   Google Scholar
• Meguid El NahasABelloAKChronic kidney disease: the global challengeLancet2005365945633134015664230
   PubMed Web of Science ®Google Scholar
• BrayFJemalAGreyNFerlayJFormanDGlobal cancer transitions according to the Human Development Index (2008–2030): a population-based studyLancet Oncol201213879080122658655
   PubMed Web of Science ®Google Scholar
• DuhMSWeinerJRWhiteLALefebvrePGreenbergPEManagement of anaemia: a critical and systematic review of the cost effectiveness of erythropoiesis-stimulating agentsPharmacoeconomics20082629912018198931
   PubMed Web of Science ®Google Scholar
• BeckerRDembekCWhiteLAGarrisonLPThe cost offsets and cost-effectiveness associated with pegylated drugs: a review of the literatureExpert Rev Pharmacoecon Outcomes Res201212677579323252359
   PubMed Web of Science ®Google Scholar
• BurnierMDouchampsJATangheALess frequent dosing of erythropoiesis stimulating agents in patients undergoing dialysis: a European multicentre cost studyJ Med Econ2009122778619450138
   PubMedGoogle Scholar
• ChurchillDNMacariosDAttardCKallichJGoereeRCosts associated with erythropoiesis-stimulating agent administration to hemodialysis patientsNephron Clin Pract20071064c193c19817596729
   PubMedGoogle Scholar
• BernardoMCrawfordPHertelJAssessment of time and practice resources required to provide weekly or monthly erythropoiesis-stimulating protein therapy to chronic kidney disease patients in the physician office settingJ Manag Care Pharm200612971472517249904
   PubMed Web of Science ®Google Scholar
• SchillerBDossSDE CockEDel AguilaMANissensonARCosts of managing anemia with erythropoiesis-stimulating agents during hemo-dialysis: a time and motion studyHemodial Int200812444144919090867
   PubMed Web of Science ®Google Scholar
• SilvaFHCVViannaCMDMSilvaFVCPUK3 Cost-effectiveness of Anemia Treatment in Dialysis Patients in Brazil: ISPOR 3rd Latin America Conference, Mexico City, Mexico, 8–10 September 2011Value in Health2011147A570
   Web of Science ®Google Scholar
• Escudero-VilaplanaVMartínez-NietoCLópez-GómezJMVega-MartínezABellón-CanoJMSanjurjo-SáezMErythropoiesis-stimulating agents in anaemia due to chronic kidney disease: a cost-minimization analysisInt J Clin Pharm201335346346823595914
   PubMed Web of Science ®Google Scholar
• Albero MolinaMDLópez-Menchero MartínezRdel Pozo FernándezCÁlvarez FernándezLSánchez RodríguezLEfficiency of monthly subcutaneous administration of methoxy-polyethylene glycol-epoetin beta (Mircera) in stable patients under hemodialysis previously treated with erythropoietinDialisis y Trasplante201334393100 Spanish
   Google Scholar
• TsaiMHFangYWLeuJGShifting darbepoetin alpha to subcutaneous methoxy polyethylene glycol-epopoetin beta of similar doses and extended dose intervals effectively maintains hemoglobin concentrations in peritoneal dialysis patientsActa Nephrologica201327299103
   Google Scholar
• Padullés-ZamoraNComas-SugrañesDPineda-Yuste MdelMJódar-MasanésRMartínez-CastelaoAUse of methoxy polyethylene glycol-epoetin beta in stage 3, 4 or 5 non-dialysis chronic kidney diseaseNefrologia201232222122722421952
   PubMed Web of Science ®Google Scholar
• OlmosVPignataroJOlmosIDanersMAssessment of Compliance to the Treatment of Anaemia in Patients Receiving a Novel ESA – Methoxy Polyethylene Glycol-Epoetin Beta (MIRCERA^®) – Versus Conventional Erythropoietin Available from: http://www.tshp.twmail.net/attachments/106_V17N4-%E5%B0%88%E9%A1%8C.pdfAccessed January 12, 2014
   Google Scholar
• MüllerAMollMSwitching hemodialysis patients from short-acting ESA to once monthly CERA: a single center experienceWorld Congress of NephrologyApril 8–12, 2011Vancouver, British Columbia Abstract SU484
   Google Scholar
• FranzSJägerCGauthierTHemoglobin levels and development of ESA dose in hemodialysis patients after conversion to CERA A multi-center observational studySwiss Medical Weekly200913945/46 Suppl 178 Abstract 8S 4.4. Annual Meeting of the Swiss Society of Nephrology; December 2–4; 2009; Interlaken, Switzerland
   Web of Science ®Google Scholar
• CynkeEBenzBFranzSStable hemoglobin values and lower dose requirements after complete conversion from epoetin beta to CERA A single center experienceSwiss Medical Weekly200913945/46 Suppl 178 Abstract 19S 53. Annual Meeting of the Swiss Society of Nephrology; December 2–4; 2009; Interlaken, Switzerland
   Web of Science ®Google Scholar
• FranzSCynkeEDevelopment of dose and costs after conversion to CERA in hemodialysis patientsSwiss Medical Weekly200813847/48 Suppl 167 Abstract 23S 69. 40th Annual Meeting of the Swiss Society of Nephrology; December 3–5; 2008; St Gallen, Switzerland
   Web of Science ®Google Scholar
• Echarri ArrietaEFernandez FerreiroFAlonso ValenteAMartinez GuitinMMartinez CalvoMCost-effectiveness analysis of patients in peritoneal dialysis with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa in Santiago de Compostela University hospital complex, SpainPoster presented at: OHP020, 17th Congress of the European Association of Hospital PharmacistsMarch 21–23, 2012Milan, Italy
   Google Scholar
• GonzalezPGomezEVargasJRenal anemia (RA) treatment in Mexican public health care institutions: an evaluation of the costs and consequencesValue in Health2009127A379A380
   Web of Science ®Google Scholar
• BezditkoNIakovlievaLMischchenkoOGerasymovaOKyrychenkoOPUK24 pharmacoeconomic aspects of use of erythropoietin drugs in patients on hemodialysis in UkraineValue in Health2012157A459
   Web of Science ®Google Scholar
• KawalecPKuzmaJSzkultecka-DebekMCost-minimization analysis: Mircera (methoxypolyethylene glycol-epoetin β) vs. Anranesp (darbepoetin α) in patients with chronic kidney disease (CKD) who are not receiving haemodialysis, in Polish settingValue in Health2009127 ISPOR 12th Annual European Congress; October 24–27; 2009; Paris, France
   Web of Science ®Google Scholar
• WalshCMBiltonRRobinsonJEPUK9 real-life dosing of erythropoiesis-stimulating agents (ESAS) in chronic kidney disease (CKD)-associated anemia: budget impactValue in Health2010137A474
   Google Scholar
• SaueressigUKwanJTDe CockESapèdeCHealthcare resource utilization for anemia management: current practice with erythropoiesis-stimulating agents and the impact of converting to once-monthly CERABlood Purif200826653754618997465
   PubMed Web of Science ®Google Scholar
• De CockEDellannaFKhellafKTime savings associated with CERA once monthly: a time-and-motion study in hemodialysis centers in five European countriesJ Med Econ201316564865623402559
   PubMedGoogle Scholar
• KlatkoWFelisiakJTime and motion study of anaemia management with erythropoiesis stimulating agents in haemodialysis units in PolandJournal of Health Policy and Outcomes Research2013218992
   Google Scholar
• SharmaAYeeJGandraSRKhanIPetersenJEstimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient populationCurr Med Res Opin201026112679268720942616
   PubMed Web of Science ®Google Scholar
• RosbergJHBen-HamadiRCremieuxPYFastenauJMPiechCTDose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anaemia : a meta-analysisClin Drug Investig20052513348
   Web of Science ®Google Scholar
• ShimamatsuKInamasuHA safe and easy introduction of darbepoetin-alpha in patients receiving maintenance hemodialysis and epoetin monotherapy: a “half-and-half ” combination therapyCurr Ther Res Clin Exp2013745824384988
   PubMedGoogle Scholar
• HiraiTNishizawaYNakazonoHHemoglobin maintenance and dosing strategies using intravenous continuous erythropoietin receptor activator in Japanese hemodialysis patientsTher Apher Dial201317549850324107278
   PubMed Web of Science ®Google Scholar
• CarreraFLokCEde FranciscoAPATRONUS InvestigatorsMaintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trialNephrol Dial Transplant201025124009401720522670
   PubMed Web of Science ®Google Scholar
• ChoiPFaroukMManamleyNAddisonJDose conversion ratio in hemodialysis patients switched from darbepoetin alfa to PEG-epoetin beta: AFFIRM studyAdv Ther201330111007101724173670
   PubMed Web of Science ®Google Scholar
• JadoulMVanrenterghemYForetMWalkerRGraySJDarbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patientsNephrol Dial Transplant200419489890315031347
   PubMed Web of Science ®Google Scholar
• TrachslerJGlückZDickenmannMParameters for successful monthly extended dosing of darbepoetin-alpha in patients undergoing hemodialysisClin Nephrol200971669770219473639
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration [webpage on the Internet]Erythropoiesis-stimulating agents (ESAs) – full versionSilver Spring, MDU.S. Food and Drug Administration2013 Available from: http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm077123.htmAccessed January 24, 2014
   Google Scholar
• EschbachJWCookJDScribnerBHFinchCAIron balance in hemodialysis patientsAnn Intern Med1977876710713931207
   PubMed Web of Science ®Google Scholar
• RambodMKovesdyCPKalantar-ZadehKCombined high serum ferritin and low iron saturation in hemodialysis patients: the role of inflammationClin J Am Soc Nephrol2008361691170118922994
   PubMed Web of Science ®Google Scholar
• Kakimoto-ShinoMToyaYKujiTFujikawaTUmemuraSChanges in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized studyTher Apher Dial Epub1242014
   Web of Science ®Google Scholar
• HashimotoTTsugawaYTsunodaMIkeeRSasakiNHashimotoNImportance of intensive iron supplementation for dialysis patients with continuous erythropoietin receptor activatorJ Am Soc Nephrol201223769A770A Abstract SA-PO570. ASN Kidney Week, October 30–November 4, 2012; San Diego, CA, USA22499589
   PubMed Web of Science ®Google Scholar
• ChangWYHenryBMMethodologic principles of cost analyses in the nursing, medical, and health services literature, 1990–1996Nurs Res19994829410410190836
   PubMed Web of Science ®Google Scholar
• RussellLBGoldMRSiegelJEDanielsNWeinsteinMCThe role of cost-effectiveness analysis in health and medicine. Panel on Cost- Effectiveness in Health and MedicineJAMA199627614117211778827972
   PubMed Web of Science ®Google Scholar
• WeinsteinMCSiegelJEGoldMRKamletMSRussellLBRecommendations of the Panel on Cost-effectiveness in Health and MedicineJAMA199627615125312588849754
   PubMed Web of Science ®Google Scholar
• SiegelJEWeinsteinMCRussellLBGoldMRRecommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and MedicineJAMA199627616133913418861994
   PubMed Web of Science ®Google Scholar
• UdvarhelyiISColditzGARaiAEpsteinAMCost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly?Ann Intern Med199211632382441530808
   PubMed Web of Science ®Google Scholar
• DrummondMFSculpherMJTorranceGO’BrienBStoddartGMethods for the Economic Evaluation of Health Care Programmes2nd edOxford, UKOxford University Press1997
   Google Scholar
• RobinsonRCost-effectiveness analysisBMJ199330769077937958219957
   PubMed Web of Science ®Google Scholar
• LefebvrePVekemanFCremieuxPYComment: the impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfaAnn Pharmacother2010443595 author reply 595–59620179253
   PubMed Web of Science ®Google Scholar
• BriggsAHO’BrienBJThe death of cost-minimization analysis?Health Econ200110217918411252048
   PubMed Web of Science ®Google Scholar
• RobinsonRCosts and cost-minimisation analysisBMJ199330769067267288401098
   PubMed Web of Science ®Google Scholar
• National Institutes of Health [webpage on the Internet]Fact sheet: Medical Subject Headings (MeSH^®)Bethesda, MDU.S. National Library of Medicine2013 Available from: https://www.nlm.nih.gov/pubs/factsheets/mesh.htmlAccessed January 24, 2014
   Google Scholar
• LopeteguiMYenPYLaiAMEmbiPJPaynePRTime Capture Tool (TimeCaT): development of a comprehensive application to support data capture for Time Motion StudiesAMIA Annu Symp Proc2012201259660523304332
   PubMedGoogle Scholar
• JelkmannWBiosimilar recombinant human erythropoietins (“epoetins”) and future erythropoiesis-stimulating treatmentsExpert Opin Biol Ther201212558159222471247
   PubMed Web of Science ®Google Scholar
• HörlWHDifferentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney diseaseDrugs201373211713023338536
   PubMed Web of Science ®Google Scholar
• BioTrends Research Group [webpage on the Internet]Should Mircera reach the U.S. market, surveyed nephorologists state that at least 40 percent of CKD-ND and dialysis patients are likely candidatesExton, PABioTrends Research Group2013 Available from: http://www.bio-trends.com/News-and-Events/Press-Releases/Mircera-Nephrolodists-State-Candidates-100113Accessed January 31, 2014
   Google Scholar